📊 LTRN Key Takeaways
Is Lantern Pharma Inc. (LTRN) a Good Investment?
Pre-revenue biotech company with improving loss trends but critically limited cash runway and no clear commercialization path visible. At current burn rate of ~3.8M per period with only 4.9M in cash, company faces existential funding pressure within 1-2 quarters unless revenue materializes or capital is raised.
Lantern Pharma is pre-revenue with persistent operating and net losses; a ~$15.7M annual operating cash burn against $4.4M in cash implies a short runway and a high likelihood of near-term, dilutive financing. While liabilities are low, debt is absent, and YoY loss metrics improved, fundamentals remain weak until sustainable revenue or sizable non-dilutive funding is secured.
Lantern Pharma Inc. Key Strengths (LTRN)
- Loss trajectory improving YoY (+17.6% net income improvement, +18.7% EPS improvement)
- Zero debt burden with manageable balance sheet liability structure
- Near-term liquidity adequate with 1.87x current ratio and 68% of assets in cash
- Debt-free balance sheet (D/E 0.00x)
- Solid near-term liquidity (current ratio 2.40x)
- Improving net loss/EPS YoY with minimal capex
LTRN Stock Risks: Lantern Pharma Inc. Investment Risks
- No revenue generation demonstrated; company remains pre-commercialization/clinical stage
- Acute cash runway depletion with negative FCF of -3.8M against only 4.9M cash on hand
- Negative ROE (-96.6%) and ROA (-46.1%) reflect unsustainable current operations without product monetization
- Limited cash runway vs. burn (−$15.68M OCF vs $4.42M cash)
- No revenue; continued operating losses and execution risk
- High dilution/going-concern risk due to likely capital raises
Key Metrics to Watch
- Quarterly cash burn rate and months of cash runway remaining
- Revenue generation timing and magnitude from clinical trial progression/product approvals
- Dates and terms of future capital raises or strategic partnerships required to extend runway
- Operating cash flow (quarterly burn)
- Cash & equivalents (runway)
Lantern Pharma Inc. (LTRN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Lantern Pharma Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
LTRN Profit Margin, ROE & Profitability Analysis
LTRN vs Healthcare Sector: How Lantern Pharma Inc. Compares
How Lantern Pharma Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Lantern Pharma Inc. Stock Overvalued? LTRN Valuation Analysis 2026
Based on fundamental analysis, Lantern Pharma Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Lantern Pharma Inc. Balance Sheet: LTRN Debt, Cash & Liquidity
LTRN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Lantern Pharma Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.93 indicates the company is currently unprofitable.
LTRN Revenue Growth, EPS Growth & YoY Performance
Lantern Pharma Inc. Dividends, Buybacks & Capital Allocation
LTRN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Lantern Pharma Inc. (CIK: 0001763950)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LTRN
What is the AI rating for LTRN?
Lantern Pharma Inc. (LTRN) has a Combined AI Grade of C from Claude (C) and ChatGPT (D) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LTRN's key strengths?
Claude: Loss trajectory improving YoY (+17.6% net income improvement, +18.7% EPS improvement). Zero debt burden with manageable balance sheet liability structure. ChatGPT: Debt-free balance sheet (D/E 0.00x). Solid near-term liquidity (current ratio 2.40x).
What are the risks of investing in LTRN?
Claude: No revenue generation demonstrated; company remains pre-commercialization/clinical stage. Acute cash runway depletion with negative FCF of -3.8M against only 4.9M cash on hand. ChatGPT: Limited cash runway vs. burn (−$15.68M OCF vs $4.42M cash). No revenue; continued operating losses and execution risk.
What is LTRN's revenue and growth?
Lantern Pharma Inc. reported revenue of N/A.
Does LTRN pay dividends?
Lantern Pharma Inc. does not currently pay dividends.
Where can I find LTRN SEC filings?
Official SEC filings for Lantern Pharma Inc. (CIK: 0001763950) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LTRN's EPS?
Lantern Pharma Inc. has a diluted EPS of $-0.30.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is LTRN's fundamental grade?
Based on our AI fundamental analysis in May 2026, Lantern Pharma Inc. has a C grade with 84% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is LTRN stock overvalued or undervalued?
Valuation metrics for LTRN: ROE of -96.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is LTRN's AI grade for 2026?
Our dual AI analysis gives Lantern Pharma Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LTRN's free cash flow?
Lantern Pharma Inc.'s operating cash flow is $-3.8M, with capital expenditures of $1.7K.
How does LTRN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -96.6% (avg: 15%), current ratio 1.87 (avg: 2).